Kolte-Patil Developers Limited (KOLTEPATIL.BO) Stock Competitors & Peer Comparison
See (KOLTEPATIL.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Real Estate - Development Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KOLTEPATIL.BO | ₹366.25 | +0.55% | 32.5B | -74.90 | -₹4.89 | N/A |
| DLF.NS | ₹673.30 | -0.38% | 1.7T | 37.53 | ₹17.94 | +0.89% |
| DLF.BO | ₹672.65 | -0.46% | 1.7T | 37.68 | ₹17.85 | +0.89% |
| LODHA.NS | ₹1,095.90 | +3.68% | 1.1T | 31.98 | ₹34.27 | +0.39% |
| LODHA.BO | ₹1,095.80 | +3.66% | 1.1T | 32.00 | ₹34.24 | +0.39% |
| PHOENIXLTD.NS | ₹2,105.80 | +2.84% | 753.1B | 63.47 | ₹33.18 | +0.12% |
| OBEROIRLTY.BO | ₹1,952.25 | +1.14% | 711.4B | 28.23 | ₹69.16 | +0.41% |
| OBEROIRLTY.NS | ₹1,953.40 | +0.98% | 710.3B | 28.13 | ₹69.44 | +0.41% |
| GODREJPROP.BO | ₹2,046.85 | +2.57% | 617.7B | 33.30 | ₹61.46 | N/A |
| GODREJPROP.NS | ₹2,046.40 | +2.50% | 616.4B | 33.08 | ₹61.86 | N/A |
Stock Comparison
KOLTEPATIL.BO vs DLF.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, DLF.NS has a market cap of 1.7T. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while DLF.NS trades at ₹673.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas DLF.NS's P/E ratio is 37.53. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to DLF.NS's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to DLF.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DLF.NS's competition here
KOLTEPATIL.BO vs DLF.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, DLF.BO has a market cap of 1.7T. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while DLF.BO trades at ₹672.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas DLF.BO's P/E ratio is 37.68. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to DLF.BO's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to DLF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DLF.BO's competition here
KOLTEPATIL.BO vs LODHA.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, LODHA.NS has a market cap of 1.1T. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while LODHA.NS trades at ₹1,095.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas LODHA.NS's P/E ratio is 31.98. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to LODHA.NS's ROE of +0.16%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to LODHA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check LODHA.NS's competition here
KOLTEPATIL.BO vs LODHA.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, LODHA.BO has a market cap of 1.1T. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while LODHA.BO trades at ₹1,095.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas LODHA.BO's P/E ratio is 32.00. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to LODHA.BO's ROE of +0.16%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to LODHA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check LODHA.BO's competition here
KOLTEPATIL.BO vs PHOENIXLTD.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, PHOENIXLTD.NS has a market cap of 753.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while PHOENIXLTD.NS trades at ₹2,105.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas PHOENIXLTD.NS's P/E ratio is 63.47. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to PHOENIXLTD.NS's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PHOENIXLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PHOENIXLTD.NS's competition here
KOLTEPATIL.BO vs OBEROIRLTY.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, OBEROIRLTY.BO has a market cap of 711.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while OBEROIRLTY.BO trades at ₹1,952.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas OBEROIRLTY.BO's P/E ratio is 28.23. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to OBEROIRLTY.BO's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to OBEROIRLTY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OBEROIRLTY.BO's competition here
KOLTEPATIL.BO vs OBEROIRLTY.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, OBEROIRLTY.NS has a market cap of 710.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while OBEROIRLTY.NS trades at ₹1,953.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas OBEROIRLTY.NS's P/E ratio is 28.13. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to OBEROIRLTY.NS's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to OBEROIRLTY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OBEROIRLTY.NS's competition here
KOLTEPATIL.BO vs GODREJPROP.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, GODREJPROP.BO has a market cap of 617.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while GODREJPROP.BO trades at ₹2,046.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas GODREJPROP.BO's P/E ratio is 33.30. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to GODREJPROP.BO's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to GODREJPROP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GODREJPROP.BO's competition here
KOLTEPATIL.BO vs GODREJPROP.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, GODREJPROP.NS has a market cap of 616.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while GODREJPROP.NS trades at ₹2,046.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas GODREJPROP.NS's P/E ratio is 33.08. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to GODREJPROP.NS's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to GODREJPROP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GODREJPROP.NS's competition here
KOLTEPATIL.BO vs ANANTRAJ.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ANANTRAJ.BO has a market cap of 199.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ANANTRAJ.BO trades at ₹550.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ANANTRAJ.BO's P/E ratio is 34.40. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ANANTRAJ.BO's ROE of +0.12%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ANANTRAJ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ANANTRAJ.BO's competition here
KOLTEPATIL.BO vs ANANTRAJ.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ANANTRAJ.NS has a market cap of 198.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ANANTRAJ.NS trades at ₹550.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ANANTRAJ.NS's P/E ratio is 35.63. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ANANTRAJ.NS's ROE of +0.12%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ANANTRAJ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ANANTRAJ.NS's competition here
KOLTEPATIL.BO vs BRIGADE.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, BRIGADE.NS has a market cap of 175.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while BRIGADE.NS trades at ₹537.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas BRIGADE.NS's P/E ratio is 21.63. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to BRIGADE.NS's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to BRIGADE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check BRIGADE.NS's competition here
KOLTEPATIL.BO vs BRIGADE.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, BRIGADE.BO has a market cap of 175.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while BRIGADE.BO trades at ₹537.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas BRIGADE.BO's P/E ratio is 21.63. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to BRIGADE.BO's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to BRIGADE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check BRIGADE.BO's competition here
KOLTEPATIL.BO vs SOBHA.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SOBHA.NS has a market cap of 155.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SOBHA.NS trades at ₹1,457.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SOBHA.NS's P/E ratio is 80.54. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SOBHA.NS's ROE of +0.04%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SOBHA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SOBHA.NS's competition here
KOLTEPATIL.BO vs SOBHA.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SOBHA.BO has a market cap of 155.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SOBHA.BO trades at ₹1,457.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SOBHA.BO's P/E ratio is 80.74. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SOBHA.BO's ROE of +0.04%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SOBHA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SOBHA.BO's competition here
KOLTEPATIL.BO vs SIGNATURE.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SIGNATURE.NS has a market cap of 110.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SIGNATURE.NS trades at ₹788.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SIGNATURE.NS's P/E ratio is 478.03. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SIGNATURE.NS's ROE of +1.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SIGNATURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SIGNATURE.NS's competition here
KOLTEPATIL.BO vs SIGNATURE.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SIGNATURE.BO has a market cap of 110.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SIGNATURE.BO trades at ₹788.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SIGNATURE.BO's P/E ratio is 489.44. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SIGNATURE.BO's ROE of +1.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SIGNATURE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SIGNATURE.BO's competition here
KOLTEPATIL.BO vs IBREALEST.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, IBREALEST.BO has a market cap of 95.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while IBREALEST.BO trades at ₹150.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas IBREALEST.BO's P/E ratio is -7.83. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to IBREALEST.BO's ROE of +0.00%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to IBREALEST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBREALEST.BO's competition here
KOLTEPATIL.BO vs IBREALEST.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, IBREALEST.NS has a market cap of 83.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while IBREALEST.NS trades at ₹131.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas IBREALEST.NS's P/E ratio is -6.85. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to IBREALEST.NS's ROE of +0.00%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to IBREALEST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBREALEST.NS's competition here
KOLTEPATIL.BO vs MAHLIFE.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, MAHLIFE.BO has a market cap of 79.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while MAHLIFE.BO trades at ₹373.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas MAHLIFE.BO's P/E ratio is 25.79. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to MAHLIFE.BO's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MAHLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAHLIFE.BO's competition here
KOLTEPATIL.BO vs MAHLIFE.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, MAHLIFE.NS has a market cap of 79.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while MAHLIFE.NS trades at ₹372.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas MAHLIFE.NS's P/E ratio is 26.78. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to MAHLIFE.NS's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MAHLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAHLIFE.NS's competition here
KOLTEPATIL.BO vs MAXESTATES.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, MAXESTATES.BO has a market cap of 78.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while MAXESTATES.BO trades at ₹480.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas MAXESTATES.BO's P/E ratio is 587.11. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to MAXESTATES.BO's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MAXESTATES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAXESTATES.BO's competition here
KOLTEPATIL.BO vs MAXESTATES.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, MAXESTATES.NS has a market cap of 77.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while MAXESTATES.NS trades at ₹476.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas MAXESTATES.NS's P/E ratio is 376.14. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to MAXESTATES.NS's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MAXESTATES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAXESTATES.NS's competition here
KOLTEPATIL.BO vs IBULLSLTD.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, IBULLSLTD.BO has a market cap of 67.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while IBULLSLTD.BO trades at ₹30.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas IBULLSLTD.BO's P/E ratio is 28.77. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to IBULLSLTD.BO's ROE of +0.21%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to IBULLSLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBULLSLTD.BO's competition here
KOLTEPATIL.BO vs IBULLSLTD.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, IBULLSLTD.NS has a market cap of 67.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while IBULLSLTD.NS trades at ₹30.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas IBULLSLTD.NS's P/E ratio is 28.67. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to IBULLSLTD.NS's ROE of +0.21%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to IBULLSLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBULLSLTD.NS's competition here
KOLTEPATIL.BO vs GANESHHOU.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, GANESHHOU.NS has a market cap of 67.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while GANESHHOU.NS trades at ₹804.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas GANESHHOU.NS's P/E ratio is 21.20. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to GANESHHOU.NS's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOU.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOU.NS's competition here
KOLTEPATIL.BO vs GANESHHOU.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, GANESHHOU.BO has a market cap of 66.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while GANESHHOU.BO trades at ₹801.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas GANESHHOU.BO's P/E ratio is 21.12. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to GANESHHOU.BO's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to GANESHHOU.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOU.BO's competition here
KOLTEPATIL.BO vs KALPATARU.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, KALPATARU.NS has a market cap of 63.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while KALPATARU.NS trades at ₹308.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas KALPATARU.NS's P/E ratio is 64.83. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to KALPATARU.NS's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to KALPATARU.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KALPATARU.NS's competition here
KOLTEPATIL.BO vs DBREALTY.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, DBREALTY.NS has a market cap of 62.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while DBREALTY.NS trades at ₹114.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas DBREALTY.NS's P/E ratio is 549.73. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to DBREALTY.NS's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to DBREALTY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DBREALTY.NS's competition here
KOLTEPATIL.BO vs DBREALTY.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, DBREALTY.BO has a market cap of 61.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while DBREALTY.BO trades at ₹114.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas DBREALTY.BO's P/E ratio is 237.71. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to DBREALTY.BO's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to DBREALTY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DBREALTY.BO's competition here
KOLTEPATIL.BO vs NIRLON.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, NIRLON.BO has a market cap of 56.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while NIRLON.BO trades at ₹622.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas NIRLON.BO's P/E ratio is 16.21. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to NIRLON.BO's ROE of +0.84%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to NIRLON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NIRLON.BO's competition here
KOLTEPATIL.BO vs RUSTOMJEE.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, RUSTOMJEE.NS has a market cap of 54.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while RUSTOMJEE.NS trades at ₹429.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas RUSTOMJEE.NS's P/E ratio is 40.37. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to RUSTOMJEE.NS's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to RUSTOMJEE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RUSTOMJEE.NS's competition here
KOLTEPATIL.BO vs RUSTOMJEE.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, RUSTOMJEE.BO has a market cap of 54.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while RUSTOMJEE.BO trades at ₹428.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas RUSTOMJEE.BO's P/E ratio is 69.01. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to RUSTOMJEE.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to RUSTOMJEE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RUSTOMJEE.BO's competition here
KOLTEPATIL.BO vs PURVA.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, PURVA.BO has a market cap of 52.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while PURVA.BO trades at ₹222.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas PURVA.BO's P/E ratio is -37.14. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to PURVA.BO's ROE of +0.04%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to PURVA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PURVA.BO's competition here
KOLTEPATIL.BO vs PURVA.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, PURVA.NS has a market cap of 52.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while PURVA.NS trades at ₹221.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas PURVA.NS's P/E ratio is -57.74. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to PURVA.NS's ROE of +0.04%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to PURVA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PURVA.NS's competition here
KOLTEPATIL.BO vs SUNTECK.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SUNTECK.NS has a market cap of 49.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SUNTECK.NS trades at ₹338.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SUNTECK.NS's P/E ratio is 23.20. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SUNTECK.NS's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SUNTECK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SUNTECK.NS's competition here
KOLTEPATIL.BO vs SUNTECK.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SUNTECK.BO has a market cap of 49.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SUNTECK.BO trades at ₹338.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SUNTECK.BO's P/E ratio is 24.32. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SUNTECK.BO's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SUNTECK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SUNTECK.BO's competition here
KOLTEPATIL.BO vs GANESHHOUC.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, GANESHHOUC.NS has a market cap of 48.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while GANESHHOUC.NS trades at ₹584.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas GANESHHOUC.NS's P/E ratio is 8.44. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to GANESHHOUC.NS's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOUC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOUC.NS's competition here
KOLTEPATIL.BO vs AGIIL.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, AGIIL.NS has a market cap of 44.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while AGIIL.NS trades at ₹356.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas AGIIL.NS's P/E ratio is 45.76. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to AGIIL.NS's ROE of +0.26%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to AGIIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AGIIL.NS's competition here
KOLTEPATIL.BO vs HEMIPROP.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, HEMIPROP.BO has a market cap of 40.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while HEMIPROP.BO trades at ₹140.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas HEMIPROP.BO's P/E ratio is -364.15. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to HEMIPROP.BO's ROE of -0.03%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to HEMIPROP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HEMIPROP.BO's competition here
KOLTEPATIL.BO vs ASHIANA.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ASHIANA.BO has a market cap of 38.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ASHIANA.BO trades at ₹381.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ASHIANA.BO's P/E ratio is 31.81. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ASHIANA.BO's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ASHIANA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ASHIANA.BO's competition here
KOLTEPATIL.BO vs ASHIANA.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ASHIANA.NS has a market cap of 38.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ASHIANA.NS trades at ₹380.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ASHIANA.NS's P/E ratio is 31.72. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ASHIANA.NS's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ASHIANA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ASHIANA.NS's competition here
KOLTEPATIL.BO vs KESAR.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, KESAR.BO has a market cap of 37.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while KESAR.BO trades at ₹1,252.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas KESAR.BO's P/E ratio is 125.42. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to KESAR.BO's ROE of +0.22%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to KESAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KESAR.BO's competition here
KOLTEPATIL.BO vs TARC.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, TARC.NS has a market cap of 36.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while TARC.NS trades at ₹124.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas TARC.NS's P/E ratio is 191.58. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to TARC.NS's ROE of +0.02%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to TARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check TARC.NS's competition here
KOLTEPATIL.BO vs TARC.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, TARC.BO has a market cap of 36.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while TARC.BO trades at ₹124.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas TARC.BO's P/E ratio is -44.20. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to TARC.BO's ROE of +0.02%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to TARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check TARC.BO's competition here
KOLTEPATIL.BO vs KOLTEPATIL.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, KOLTEPATIL.NS has a market cap of 32.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while KOLTEPATIL.NS trades at ₹365.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas KOLTEPATIL.NS's P/E ratio is -73.93. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to KOLTEPATIL.NS's ROE of -0.04%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to KOLTEPATIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KOLTEPATIL.NS's competition here
KOLTEPATIL.BO vs HUBTOWN.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, HUBTOWN.NS has a market cap of 30.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while HUBTOWN.NS trades at ₹217.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas HUBTOWN.NS's P/E ratio is 41.43. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to HUBTOWN.NS's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to HUBTOWN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HUBTOWN.NS's competition here
KOLTEPATIL.BO vs HUBTOWN.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, HUBTOWN.BO has a market cap of 30.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while HUBTOWN.BO trades at ₹217.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas HUBTOWN.BO's P/E ratio is 20.34. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to HUBTOWN.BO's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to HUBTOWN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HUBTOWN.BO's competition here
KOLTEPATIL.BO vs MARATHON.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, MARATHON.BO has a market cap of 28.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while MARATHON.BO trades at ₹420.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas MARATHON.BO's P/E ratio is 12.73. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to MARATHON.BO's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MARATHON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MARATHON.BO's competition here
KOLTEPATIL.BO vs MARATHON.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, MARATHON.NS has a market cap of 28.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while MARATHON.NS trades at ₹420.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas MARATHON.NS's P/E ratio is 13.18. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to MARATHON.NS's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MARATHON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MARATHON.NS's competition here
KOLTEPATIL.BO vs ARVSMART.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ARVSMART.BO has a market cap of 28B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ARVSMART.BO trades at ₹607.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ARVSMART.BO's P/E ratio is 26.24. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ARVSMART.BO's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ARVSMART.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARVSMART.BO's competition here
KOLTEPATIL.BO vs ARVSMART.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ARVSMART.NS has a market cap of 27.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ARVSMART.NS trades at ₹608.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ARVSMART.NS's P/E ratio is 25.12. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ARVSMART.NS's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ARVSMART.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARVSMART.NS's competition here
KOLTEPATIL.BO vs AJMERA.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, AJMERA.NS has a market cap of 26.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while AJMERA.NS trades at ₹132.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas AJMERA.NS's P/E ratio is 17.38. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to AJMERA.NS's ROE of +0.12%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to AJMERA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AJMERA.NS's competition here
KOLTEPATIL.BO vs AJMERA.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, AJMERA.BO has a market cap of 26B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while AJMERA.BO trades at ₹132.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas AJMERA.BO's P/E ratio is 17.35. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to AJMERA.BO's ROE of +0.12%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to AJMERA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AJMERA.BO's competition here
KOLTEPATIL.BO vs ALEMBICLTD.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ALEMBICLTD.BO has a market cap of 23.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ALEMBICLTD.BO trades at ₹91.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ALEMBICLTD.BO's P/E ratio is 7.43. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ALEMBICLTD.BO's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ALEMBICLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ALEMBICLTD.BO's competition here
KOLTEPATIL.BO vs ALEMBICLTD.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ALEMBICLTD.NS has a market cap of 23.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ALEMBICLTD.NS trades at ₹91.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ALEMBICLTD.NS's P/E ratio is 7.42. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ALEMBICLTD.NS's competition here
KOLTEPATIL.BO vs ARKADE.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ARKADE.NS has a market cap of 23.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ARKADE.NS trades at ₹124.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ARKADE.NS's P/E ratio is 430.83. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ARKADE.NS's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ARKADE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARKADE.NS's competition here
KOLTEPATIL.BO vs OMAXE.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, OMAXE.BO has a market cap of 16.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while OMAXE.BO trades at ₹90.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas OMAXE.BO's P/E ratio is -2.36. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to OMAXE.BO's ROE of +1.50%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OMAXE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OMAXE.BO's competition here
KOLTEPATIL.BO vs OMAXE.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, OMAXE.NS has a market cap of 16.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while OMAXE.NS trades at ₹89.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas OMAXE.NS's P/E ratio is -2.49. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to OMAXE.NS's ROE of +1.50%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OMAXE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OMAXE.NS's competition here
KOLTEPATIL.BO vs SHRIRAMPPS.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SHRIRAMPPS.NS has a market cap of 15.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SHRIRAMPPS.NS trades at ₹91.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SHRIRAMPPS.NS's P/E ratio is 19.35. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SHRIRAMPPS.NS's ROE of +0.07%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SHRIRAMPPS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SHRIRAMPPS.NS's competition here
KOLTEPATIL.BO vs NATIONSTD.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, NATIONSTD.BO has a market cap of 15.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while NATIONSTD.BO trades at ₹777.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas NATIONSTD.BO's P/E ratio is 188.70. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to NATIONSTD.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NATIONSTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NATIONSTD.BO's competition here
KOLTEPATIL.BO vs SHRIRAMPPS.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SHRIRAMPPS.BO has a market cap of 15.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SHRIRAMPPS.BO trades at ₹91.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SHRIRAMPPS.BO's P/E ratio is 84.53. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SHRIRAMPPS.BO's ROE of +0.07%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SHRIRAMPPS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SHRIRAMPPS.BO's competition here
KOLTEPATIL.BO vs ASL.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ASL.BO has a market cap of 12.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ASL.BO trades at ₹310.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ASL.BO's P/E ratio is -1320.85. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ASL.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ASL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ASL.BO's competition here
KOLTEPATIL.BO vs UNITECH.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, UNITECH.NS has a market cap of 12.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while UNITECH.NS trades at ₹4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas UNITECH.NS's P/E ratio is -0.50. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to UNITECH.NS's ROE of +0.30%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to UNITECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check UNITECH.NS's competition here
KOLTEPATIL.BO vs UNITECH.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, UNITECH.BO has a market cap of 12.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while UNITECH.BO trades at ₹4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas UNITECH.BO's P/E ratio is -0.50. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to UNITECH.BO's ROE of +0.30%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to UNITECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check UNITECH.BO's competition here
KOLTEPATIL.BO vs ARIHANTSUP.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ARIHANTSUP.NS has a market cap of 11.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ARIHANTSUP.NS trades at ₹270.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ARIHANTSUP.NS's P/E ratio is 42.13. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ARIHANTSUP.NS's ROE of +0.07%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANTSUP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANTSUP.NS's competition here
KOLTEPATIL.BO vs ARIHANTSUP.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ARIHANTSUP.BO has a market cap of 11.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ARIHANTSUP.BO trades at ₹270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ARIHANTSUP.BO's P/E ratio is 26.14. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ARIHANTSUP.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANTSUP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANTSUP.BO's competition here
KOLTEPATIL.BO vs SURAJEST.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SURAJEST.NS has a market cap of 9.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SURAJEST.NS trades at ₹204.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SURAJEST.NS's P/E ratio is 9.83. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SURAJEST.NS's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SURAJEST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SURAJEST.NS's competition here
KOLTEPATIL.BO vs BRRL.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, BRRL.BO has a market cap of 9.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while BRRL.BO trades at ₹938.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas BRRL.BO's P/E ratio is 27.58. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to BRRL.BO's ROE of +0.22%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to BRRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check BRRL.BO's competition here
KOLTEPATIL.BO vs MCCHRLS-B.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, MCCHRLS-B.BO has a market cap of 9.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while MCCHRLS-B.BO trades at ₹705.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas MCCHRLS-B.BO's P/E ratio is -15.45. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to MCCHRLS-B.BO's ROE of -2.09%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MCCHRLS-B.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MCCHRLS-B.BO's competition here
KOLTEPATIL.BO vs RDBRIL.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, RDBRIL.BO has a market cap of 9.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while RDBRIL.BO trades at ₹53.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas RDBRIL.BO's P/E ratio is 213.12. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to RDBRIL.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RDBRIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RDBRIL.BO's competition here
KOLTEPATIL.BO vs AGIIL.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, AGIIL.BO has a market cap of 8.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while AGIIL.BO trades at ₹356.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas AGIIL.BO's P/E ratio is 24.98. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to AGIIL.BO's ROE of +0.27%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to AGIIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AGIIL.BO's competition here
KOLTEPATIL.BO vs ARIHANT.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ARIHANT.BO has a market cap of 7.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ARIHANT.BO trades at ₹797.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ARIHANT.BO's P/E ratio is 75.56. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ARIHANT.BO's ROE of +0.18%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANT.BO's competition here
KOLTEPATIL.BO vs GEECEE.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, GEECEE.BO has a market cap of 7.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while GEECEE.BO trades at ₹361.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas GEECEE.BO's P/E ratio is 17.98. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to GEECEE.BO's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to GEECEE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GEECEE.BO's competition here
KOLTEPATIL.BO vs GEECEE.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, GEECEE.NS has a market cap of 7.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while GEECEE.NS trades at ₹351.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas GEECEE.NS's P/E ratio is 17.48. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to GEECEE.NS's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GEECEE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GEECEE.NS's competition here
KOLTEPATIL.BO vs ARIHANT.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, ARIHANT.NS has a market cap of 6.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while ARIHANT.NS trades at ₹789.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas ARIHANT.NS's P/E ratio is 282.42. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to ARIHANT.NS's ROE of +0.18%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANT.NS's competition here
KOLTEPATIL.BO vs MODIS.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, MODIS.BO has a market cap of 6.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while MODIS.BO trades at ₹342.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas MODIS.BO's P/E ratio is 23.00. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to MODIS.BO's ROE of +0.28%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MODIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MODIS.BO's competition here
KOLTEPATIL.BO vs SHRADDHA.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SHRADDHA.BO has a market cap of 6.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SHRADDHA.BO trades at ₹150.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SHRADDHA.BO's P/E ratio is 11.40. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SHRADDHA.BO's ROE of +0.56%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SHRADDHA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SHRADDHA.BO's competition here
KOLTEPATIL.BO vs PANSARI.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, PANSARI.NS has a market cap of 5.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while PANSARI.NS trades at ₹333.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas PANSARI.NS's P/E ratio is 26.31. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to PANSARI.NS's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PANSARI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PANSARI.NS's competition here
KOLTEPATIL.BO vs HAZOOR.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, HAZOOR.BO has a market cap of 5.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while HAZOOR.BO trades at ₹24.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas HAZOOR.BO's P/E ratio is 13.83. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to HAZOOR.BO's ROE of +0.08%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to HAZOOR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HAZOOR.BO's competition here
KOLTEPATIL.BO vs OSWALAGRO.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, OSWALAGRO.BO has a market cap of 5.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while OSWALAGRO.BO trades at ₹41.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas OSWALAGRO.BO's P/E ratio is -25.18. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to OSWALAGRO.BO's ROE of -0.02%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to OSWALAGRO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OSWALAGRO.BO's competition here
KOLTEPATIL.BO vs OSWALAGRO.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, OSWALAGRO.NS has a market cap of 5.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while OSWALAGRO.NS trades at ₹41.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas OSWALAGRO.NS's P/E ratio is -25.19. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to OSWALAGRO.NS's ROE of -0.02%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OSWALAGRO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OSWALAGRO.NS's competition here
KOLTEPATIL.BO vs PENINLAND.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, PENINLAND.BO has a market cap of 5.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while PENINLAND.BO trades at ₹15.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas PENINLAND.BO's P/E ratio is -3.40. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to PENINLAND.BO's ROE of -0.84%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PENINLAND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PENINLAND.BO's competition here
KOLTEPATIL.BO vs PENINLAND.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, PENINLAND.NS has a market cap of 5.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while PENINLAND.NS trades at ₹15.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas PENINLAND.NS's P/E ratio is -3.38. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to PENINLAND.NS's ROE of -0.84%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PENINLAND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PENINLAND.NS's competition here
KOLTEPATIL.BO vs NILASPACES.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, NILASPACES.NS has a market cap of 5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while NILASPACES.NS trades at ₹12.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas NILASPACES.NS's P/E ratio is 17.37. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to NILASPACES.NS's ROE of +0.19%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to NILASPACES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILASPACES.NS's competition here
KOLTEPATIL.BO vs NILASPACES.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, NILASPACES.BO has a market cap of 5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while NILASPACES.BO trades at ₹12.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas NILASPACES.BO's P/E ratio is 17.37. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to NILASPACES.BO's ROE of +0.19%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to NILASPACES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILASPACES.BO's competition here
KOLTEPATIL.BO vs YOGI.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, YOGI.BO has a market cap of 4.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while YOGI.BO trades at ₹173.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas YOGI.BO's P/E ratio is 37.53. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to YOGI.BO's ROE of +0.17%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to YOGI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check YOGI.BO's competition here
KOLTEPATIL.BO vs RDBIPL.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, RDBIPL.BO has a market cap of 4.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while RDBIPL.BO trades at ₹19.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas RDBIPL.BO's P/E ratio is 31.11. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to RDBIPL.BO's ROE of +0.04%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RDBIPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RDBIPL.BO's competition here
KOLTEPATIL.BO vs SBGLP.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SBGLP.NS has a market cap of 4.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SBGLP.NS trades at ₹25.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SBGLP.NS's P/E ratio is 11.37. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SBGLP.NS's ROE of +0.47%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SBGLP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SBGLP.NS's competition here
KOLTEPATIL.BO vs SBGLP.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SBGLP.BO has a market cap of 4.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SBGLP.BO trades at ₹25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SBGLP.BO's P/E ratio is 11.52. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SBGLP.BO's ROE of +0.47%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SBGLP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SBGLP.BO's competition here
KOLTEPATIL.BO vs EMAMIREAL.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, EMAMIREAL.NS has a market cap of 3.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while EMAMIREAL.NS trades at ₹85.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas EMAMIREAL.NS's P/E ratio is -2.04. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to EMAMIREAL.NS's ROE of +1.06%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to EMAMIREAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check EMAMIREAL.NS's competition here
KOLTEPATIL.BO vs EMAMIREAL.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, EMAMIREAL.BO has a market cap of 3.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while EMAMIREAL.BO trades at ₹86.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas EMAMIREAL.BO's P/E ratio is -1.74. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to EMAMIREAL.BO's ROE of +1.06%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to EMAMIREAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check EMAMIREAL.BO's competition here
KOLTEPATIL.BO vs NILAINFRA.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, NILAINFRA.NS has a market cap of 3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while NILAINFRA.NS trades at ₹7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas NILAINFRA.NS's P/E ratio is 13.02. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to NILAINFRA.NS's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to NILAINFRA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILAINFRA.NS's competition here
KOLTEPATIL.BO vs MERCANTILE.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, MERCANTILE.BO has a market cap of 2.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while MERCANTILE.BO trades at ₹25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas MERCANTILE.BO's P/E ratio is 324.88. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to MERCANTILE.BO's ROE of +0.02%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MERCANTILE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MERCANTILE.BO's competition here
KOLTEPATIL.BO vs RVHL.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, RVHL.BO has a market cap of 2.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while RVHL.BO trades at ₹44.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas RVHL.BO's P/E ratio is -165.23. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to RVHL.BO's ROE of +0.19%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RVHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RVHL.BO's competition here
KOLTEPATIL.BO vs RVHL.NS Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, RVHL.NS has a market cap of 2.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while RVHL.NS trades at ₹43.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas RVHL.NS's P/E ratio is 45.62. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to RVHL.NS's ROE of +0.19%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RVHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RVHL.NS's competition here
KOLTEPATIL.BO vs RATNABHUMI.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, RATNABHUMI.BO has a market cap of 2.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while RATNABHUMI.BO trades at ₹191.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas RATNABHUMI.BO's P/E ratio is 428.40. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to RATNABHUMI.BO's ROE of +0.07%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to RATNABHUMI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RATNABHUMI.BO's competition here
KOLTEPATIL.BO vs SVGLOBAL.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, SVGLOBAL.BO has a market cap of 2.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while SVGLOBAL.BO trades at ₹141.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas SVGLOBAL.BO's P/E ratio is 88.72. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to SVGLOBAL.BO's ROE of -0.14%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SVGLOBAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SVGLOBAL.BO's competition here
KOLTEPATIL.BO vs TULIVE.BO Comparison July 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 32.5B. In comparison, TULIVE.BO has a market cap of 2.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹366.25, while TULIVE.BO trades at ₹1,170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of -74.90, whereas TULIVE.BO's P/E ratio is -221.17. In terms of profitability, KOLTEPATIL.BO's ROE is -0.04%, compared to TULIVE.BO's ROE of -0.05%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to TULIVE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check TULIVE.BO's competition here